Beximco Pharma Pale Hawa | Daily StockBangladesh

Staff Reporter: Beximco Pharmaceuticals shares are rising in the capital market. After the UK approved the use of Malnupiravi in ​​the treatment of Corona on November 4 this year, several companies including SKF and Beximco Pharmaceuticals took the initiative to bring the drug to the Bangladesh market.

Beximco Pharma’s share price continued to rise after the approval. Even before that, prices have been rising slightly since August 29 this year. Although the fundamentals of the company have risen and fallen since then, prices have continued to rise since November 4.

Beximco Pharmaceuticals’ share price graph was taken from Stock Bangladesh on Thursday afternoon

On November 4, the share price was 165 rupees. At the end of four working days, the transaction was completed on Thursday at 175 rupees. At the end of the day, 342 crore 72 lakh shares were traded.

Which is 22.7 percent of the total transactions on the Dhaka Stock Exchange. A total of 1 crore 8 lakh 9 thousand 47 shares of Beximco Pharma have been exchanged.

The company’s share price has risen since the start of trading on Wednesday and by 12 noon the company’s share price had risen by Tk 8.30 paise or 2.62 percent.

In the meantime, they have applied to the Department of Drug Administration, which later allowed SKF and Beximco Pharmaceuticals to market the drug Malnupiravi on an urgent basis.

The effect is seen in the share price of the company. Bexrimco Pharma brings to Bangladesh the Oxford-AstraZeneca Corona vaccine, previously developed by the Serum Institute of India.


Source: Daily StockBangladesh by www.dailystockbangladesh.com.

*The article has been translated based on the content of Daily StockBangladesh by www.dailystockbangladesh.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!